Abstract
BackgroundDecades of encouraging yet incomplete responses from cytotoxic (CD8+) T cell-based cancer immunotherapies have invigorated recent efforts to develop highly tunable, robust, and more cost-effective artificial antigen presenting cells (aAPCs)....
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
